- Details
- Description
LuciZonger (zongertinib) is an oral targeted anticancer medicine containing zongertinib, a kinase inhibitor that selectively targets HER2 (ERBB2). It is designed for the treatment of certain adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations confirmed by an appropriate diagnostic test.
Zongertinib works by inhibiting HER2 signaling involved in the growth and proliferation of cancer cells. It is administered orally as film-coated tablets. The product information for LuciZonger describes a 60 mg tablet presentation.
Important: Zongertinib is a prescription oncology medicine and should be used under the supervision of a qualified healthcare professional. Important risks include liver toxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.
